查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
循環腫瘤細胞市場:世界的市場機會分析及產業預測，2020-2030年市場
市場調查報告書
商品編碼
1147375

循環腫瘤細胞市場:世界的市場機會分析及產業預測，2020-2030年市場

Circulating Tumor Cell Market: Global Opportunity Analysis and Industry Forecast, 2020-2030 Market
出版日期: | 出版商: Allied Market Research | 英文 | 商品交期: 2-3個工作天內

價格
簡介目錄

循環腫瘤細胞檢驗，能查出癌症患者血液中的癌細胞，並定量化。

CTC中存在各種生物學表型，包括上皮、間充質、幹細胞和混合細胞。這些細胞在血液中的含量非常少，而且數量遠少於其他細胞(尤其是白細胞)。因此，CTC的檢測需要分離/濃縮步驟和第二檢測步驟。循環腫瘤細胞在診斷前、治療前以及治療中和治療後的許多潛在應用為參與循環腫瘤細胞 (CTC) 濃縮和分離產品開發的參與者提供了有利的成長機會。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場情勢

  • 市場定義和範圍
  • 主要的調查結果
    • 最高層的投資處
    • 主要的成功策略
  • 波特的五力分析
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
    • 買方議價能力
  • 市場情況分析/龍頭企業定位
    • 2021年市場佔有率分析/龍頭企業定位
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • COVID-19影響分析

第4章 循環腫瘤細胞市場:各技術

  • 市場概要
    • 市場規模、預測:各技術
  • CTC檢測濃縮方法
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國
  • CTC直接檢測法
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國
  • CTC分析
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國

第5章 循環腫瘤細胞市場:各應用領域

  • 市場概要
    • 市場規模、預測:各應用領域
  • 臨床/液態切片
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國
    • 風險評估
      • 市場規模及預測
    • 篩檢和監測
      • 市場規模與預測
  • 調查
    • 主要的市場趨勢，成長要素，機會等
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國
    • 癌症幹細胞的腫瘤形成研究
      • 市場規模、預測
    • 醫藥品/開發治療
      • 市場規模、預測

第6章 循環腫瘤細胞市場:各終端用戶

  • 市場概要
    • 市場規模、預測:各終端用戶
  • 醫院診所
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國
  • 研究學術機構
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國
  • 診斷中心
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場佔有率分析:各國

第7章 循環腫瘤細胞市場:各地區

  • 市場概要
    • 市場規模、預測:各地區
  • 北美
    • 主要市場趨勢與商機
    • 市場規模、預測:各技術
    • 市場規模、預測:各應用領域
    • 市場規模、預測:各終端用戶
    • 市場規模、預測:各國
    • 美國的循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 加拿大循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 墨西哥的循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
  • 歐洲
    • 主要的市場趨勢與機會
    • 市場規模、預測:各科技
    • 市場規模、預測:各應用領域
    • 市場規模、預測:各終端用戶
    • 市場規模、預測:各國
    • 法國循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 德國循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 義大利循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 西班牙循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 英國循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 其他歐洲的循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
  • 亞太地區
    • 主要的市場趨勢與機會
    • 亞太地區的市場規模、預測:各科技
    • 亞太地區的市場規模、預測:各應用領域
    • 亞太地區的市場規模、預測:各終端用戶
    • 市場規模、預測:各國
    • 中國循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 日本循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 印度循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 韓國循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 澳洲循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 其他亞太地區的循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
  • LAMEA
    • 主要的市場趨勢與機會
    • 市場規模、預測:各科技
    • 市場規模、預測:各應用領域
    • 市場規模、預測:各終端用戶
    • 市場規模、預測:各國
    • 巴西循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 南非循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • 沙烏地阿拉伯的循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • UAE循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶
    • LAMEA的其他地區循環腫瘤細胞市場
      • 市場規模及預測:各技術
      • 市場規模及預測:各應用領域
      • 市場規模及預測:各終端用戶

第8章 企業簡介

  • Ikonisys Inc.
  • Greiner Bio-One International GmbH
  • Thermo Fisher Scientific
  • SRI International
  • STEMCELL Technologies
  • Miltenyi Biotec
  • Menarini Silicon Biosystems
  • QIAGEN Hannover(QIAGEN)
  • F. Hoffmann-La Roche Ltd.
  • NanoString Technologies, Inc
簡介目錄
Product Code: A11918

Circulating tumor cell testing enables the detection and quantification of tumor cells in the blood of cancer patients. Different biological phenotypes of CTCs exist: epithelial, mesenchymal, stem cell-like or mixed. They are present in blood in very small quantities, vastly outnumbered by other cells, especially white blood cells. As a result, their detection needs a phase of isolation-enrichment and a second phase of detection. All the recent CTC identification devices combine these two steps (isolation-enrichment and detection) such as ISET, CellSearch System, CTC-chip or EPISPOT. Sometimes, different methods are used in the same device for one step: for instance, the RosetteSep device includes 2 methods of enrichment/isolation: by density and by immunologic separation which is a negative selection. A number of potential applications of circulating tumor cells in prediagnosis, pre-treatment, and intra and post-treatment provide lucrative growth opportunities to players involved in the development of circulating tumor cell (CTC) enrichment and isolation products.

Covid-19 Scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the circulating tumour cell market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Increased demand for efficient diagnostic and screening tests and technological advancements in cancer detection is expected to propel the growth of market for CTCs. Several tumor markers that have been introduced in recent years can be used with companion diagnostics to monitor or diagnose a variety of cancers. High adoption of companion diagnostics in monitoring tumor eradication characteristics of cytotoxic drugs is among the few factors propelling the demand in the market for CTCs. Key stakeholders are constantly engaged in endeavours aimed at developing circulating tumor cells based tests, which can prove helpful in the cancer diagnosis. The circulating tumor cell testing is also a useful tool for the development of preventive medicine for cancer. Circulating tumor cell testing can help understand and asses the mechanism of drug during in-vitro experiment in preclinical studies.

Drivers:

Increase in preference for minimum invasive procedure:

Growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. Circulating tumor cell based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

Increase in prevalence rate of cancer:

The growing prevalence of cancer is one of the major reasons behind the growth of circulating tumor cell testing market. According to NIH, National Cancer Institute, cancer is one of the major reasons of death globally. According to an estimation from the National Cancer Institute, in 2018 colorectal cancer is projected to contribute around 8.1% of all new cancer cases with estimated deaths around 50,630, which is 8.3% of all cancer deaths caused in the U.S.As reported by the Cancer Research UK, there were 41,804 new cases of colorectal cancer in 2015 and 16,384 deaths due to colon cancer in the U.K. Increase in genetic disorder, alcohol consumption, smoking and lifestyle changes are the major factor behind the rise in cancer cases and also contributing factor for the growth of the circulating tumor cell market.

Key Market players:

  • In March 2018, Biocept Inc received a patent for its Target Selector assays for molecular analysis to improve the patient diagnosis with cancer in China.
  • In May 2021, Natera, a company involved in non-invasive genetic testing and the analysis of circulating cell-free DNA, to present successful results of Signatera, to monitor colorectal cancer and identify disease recurrence.

Key benefits of the report:

  • This study presents the analytical depiction of the global circulating tumor cell industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global circulating tumor cell market share.
  • The current market is quantitatively analyzed from 2021 to 2030 to highlight the global circulating tumor cell market growth scenario.
  • Porter's five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global circulating tumor cell market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Circulating tumor cell Market research report:

  • What are the leading market players active in the circulating tumor cell market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Share Analysis/Top Player Positioning
    • 3.4.1. Market Share Analysis/Top Player Positioning 2021
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities
  • 3.6. COVID-19 Impact Analysis

CHAPTER 4: CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY

  • 4.1. Market Overview
    • 4.1.1. Market Size and Forecast, By Technology
  • 4.2. CTC Detection Enrichment Method
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. CTC Direct Detection Methods
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. CTC Analysis
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CIRCULATING TUMOR CELL MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1. Market Size and Forecast, By Application
  • 5.2. Clinical/Liquid Biopsy
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
    • 5.2.4. Risk Assessment
      • 5.2.4.1. Market Size and Forecast
    • 5.2.4. Screening and Monitoring
      • 5.2.4.1. Market Size and Forecast
  • 5.3. Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
    • 5.3.4. Cancer Stem Cell Tumorigenesis Research
      • 5.3.4.1. Market Size and Forecast
    • 5.3.4. Drug/Therapy Development
      • 5.3.4.1. Market Size and Forecast

CHAPTER 6: CIRCULATING TUMOR CELL MARKET, BY END USERS

  • 6.1. Market Overview
    • 6.1.1. Market Size and Forecast, By End Users
  • 6.2. Hospital Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Research Academic Institutes
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Centres
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CIRCULATING TUMOR CELL MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1. Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Technology
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End Users
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Circulating Tumor Cell Market
      • 7.2.6.1. Market Size and Forecast, By Technology
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End Users
    • 7.2.7. Canada Circulating Tumor Cell Market
      • 7.2.7.1. Market Size and Forecast, By Technology
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End Users
    • 7.2.8. Mexico Circulating Tumor Cell Market
      • 7.2.8.1. Market Size and Forecast, By Technology
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End Users
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Technology
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End Users
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Circulating Tumor Cell Market
      • 7.3.6.1. Market Size and Forecast, By Technology
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End Users
    • 7.3.7. Germany Circulating Tumor Cell Market
      • 7.3.7.1. Market Size and Forecast, By Technology
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End Users
    • 7.3.8. Italy Circulating Tumor Cell Market
      • 7.3.8.1. Market Size and Forecast, By Technology
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End Users
    • 7.3.9. Spain Circulating Tumor Cell Market
      • 7.3.9.1. Market Size and Forecast, By Technology
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End Users
    • 7.3.10. UK Circulating Tumor Cell Market
      • 7.3.10.1. Market Size and Forecast, By Technology
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End Users
    • 7.3.11. Rest Of Europe Circulating Tumor Cell Market
      • 7.3.11.1. Market Size and Forecast, By Technology
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End Users
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Technology
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End Users
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Circulating Tumor Cell Market
      • 7.4.6.1. Market Size and Forecast, By Technology
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End Users
    • 7.4.7. Japan Circulating Tumor Cell Market
      • 7.4.7.1. Market Size and Forecast, By Technology
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End Users
    • 7.4.8. India Circulating Tumor Cell Market
      • 7.4.8.1. Market Size and Forecast, By Technology
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End Users
    • 7.4.9. South Korea Circulating Tumor Cell Market
      • 7.4.9.1. Market Size and Forecast, By Technology
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End Users
    • 7.4.10. Australia Circulating Tumor Cell Market
      • 7.4.10.1. Market Size and Forecast, By Technology
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End Users
    • 7.4.11. Rest of Asia Pacific Circulating Tumor Cell Market
      • 7.4.11.1. Market Size and Forecast, By Technology
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End Users
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Technology
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End Users
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Circulating Tumor Cell Market
      • 7.5.6.1. Market Size and Forecast, By Technology
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End Users
    • 7.5.7. South Africa Circulating Tumor Cell Market
      • 7.5.7.1. Market Size and Forecast, By Technology
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End Users
    • 7.5.8. Saudi Arabia Circulating Tumor Cell Market
      • 7.5.8.1. Market Size and Forecast, By Technology
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End Users
    • 7.5.9. UAE Circulating Tumor Cell Market
      • 7.5.9.1. Market Size and Forecast, By Technology
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End Users
    • 7.5.10. Rest of LAMEA Circulating Tumor Cell Market
      • 7.5.10.1. Market Size and Forecast, By Technology
      • 7.5.10.2. Market Size and Forecast, By Application
      • 7.5.10.3. Market Size and Forecast, By End Users

CHAPTER 8: COMPANY PROFILES

  • 8.1. Ikonisys Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Greiner Bio-One International GmbH
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Thermo Fisher Scientific
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. SRI International
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. STEMCELL Technologies
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Miltenyi Biotec
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Menarini Silicon Biosystems
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. QIAGEN Hannover (QIAGEN)
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. F. Hoffmann-La Roche Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. NanoString Technologies, Inc
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Development